Literature DB >> 24813090

Estimating functional liver reserve following hepatic irradiation: adaptive normal tissue response models.

Matthew H Stenmark1, Yue Cao2, Hesheng Wang3, Andrew Jackson4, Edgar Ben-Josef5, Randall K Ten Haken3, Theodore S Lawrence3, Mary Feng3.   

Abstract

PURPOSE: To estimate the limit of functional liver reserve for safe application of hepatic irradiation using changes in indocyanine green, an established assay of liver function.
MATERIALS AND METHODS: From 2005 to 2011, 60 patients undergoing hepatic irradiation were enrolled in a prospective study assessing the plasma retention fraction of indocyanine green at 15-min (ICG-R15) prior to, during (at 60% of planned dose), and after radiotherapy (RT). The limit of functional liver reserve was estimated from the damage fraction of functional liver (DFL) post-RT [1-(ICG-R15pre-RT/ICG-R15post-RT)] where no toxicity was observed using a beta distribution function.
RESULTS: Of 48 evaluable patients, 3 (6%) developed RILD, all within 2.5 months of completing RT. The mean ICG-R15 for non-RILD patients pre-RT, during-RT and 1-month post-RT was 20.3%(SE 2.6), 22.0%(3.0), and 27.5%(2.8), and for RILD patients was 6.3%(4.3), 10.8%(2.7), and 47.6%(8.8). RILD was observed at post-RT damage fractions of ≥78%. Both DFL assessed by during-RT ICG and MLD predicted for DFL post-RT (p<0.0001). Limiting the post-RT DFL to 50%, predicted a 99% probability of a true complication rate <15%.
CONCLUSION: The DFL as assessed by changes in ICG during treatment serves as an early indicator of a patient's tolerance to hepatic irradiation. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Adaptive radiotherapy; Indocyanine green; Liver; Radiotherapy

Mesh:

Substances:

Year:  2014        PMID: 24813090      PMCID: PMC4119482          DOI: 10.1016/j.radonc.2014.04.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

1.  Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients.

Authors:  Jinsil Seong; Hee Chul Park; Kwang Hyub Han; Chae Yoon Chon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

Review 2.  Radiation-associated liver injury.

Authors:  Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.

Authors:  Mary Feng; David E Smith; Daniel P Normolle; James A Knol; Charlie C Pan; Edgar Ben-Josef; Zheng Lu; Meihua R Feng; Jun Chen; William Ensminger; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-21       Impact factor: 7.038

4.  Adaptive trial of personalized radiotherapy for intrahepatic cancer.

Authors:  Daniel Normolle; Charlie Pan; Edgar Ben-Josef; Theodore Lawrence
Journal:  Per Med       Date:  2010       Impact factor: 2.512

5.  An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy.

Authors:  T S Lawrence; R J Tesser; R K ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

6.  Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test.

Authors:  Hiroshi Imamura; Keiji Sano; Yasuhiko Sugawara; Norihiko Kokudo; Masatoshi Makuuchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2005

7.  Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy.

Authors:  Ik Jae Lee; Jinsil Seong; Su Jung Shim; Kwang Hyub Han
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-25       Impact factor: 7.038

8.  Indocyanine green. Its use as an early indicator of hepatic dysfunction following injury in man.

Authors:  M E Gottlieb; H H Stratton; J C Newell; D M Shah
Journal:  Arch Surg       Date:  1984-03

9.  Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma.

Authors:  Zhi-Yong Xu; Shi-Xiong Liang; Ji Zhu; Xiao-Dong Zhu; Jian-Dong Zhao; Hai-Jie Lu; Yun-Li Yang; Long Chen; An-Yu Wang; Xiao-Long Fu; Guo-Liang Jiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

10.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

Authors:  Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson
Journal:  J Clin Oncol       Date:  2008-01-02       Impact factor: 44.544

View more
  16 in total

1.  Technology for Innovation in Radiation Oncology.

Authors:  Indrin J Chetty; Mary K Martel; David A Jaffray; Stanley H Benedict; Stephen M Hahn; Ross Berbeco; James Deye; Robert Jeraj; Brian Kavanagh; Sunil Krishnan; Nancy Lee; Daniel A Low; David Mankoff; Lawrence B Marks; Daniel Ollendorf; Harald Paganetti; Brian Ross; Ramon Alfredo C Siochi; Robert D Timmerman; John W Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-11       Impact factor: 7.038

2.  Laparoscopic versus open mesohepatectomy for patients with centrally located hepatocellular carcinoma: a propensity score matched analysis.

Authors:  Wei Li; Jun Han; Guowei Xie; Yang Xiao; Ke Sun; Kefei Yuan; Hong Wu
Journal:  Surg Endosc       Date:  2018-11-29       Impact factor: 4.584

3.  A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Authors:  W C Jackson; K Suresh; C Maurino; M Feng; K C Cuneo; R K Ten Haken; T S Lawrence; M J Schipper; D Owen
Journal:  Radiother Oncol       Date:  2019-08-17       Impact factor: 6.280

Review 4.  Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities.

Authors:  Payal D Soni; Manisha Palta
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 5.  Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.

Authors:  Christopher H Crane; Eugene J Koay
Journal:  Cancer       Date:  2016-03-07       Impact factor: 6.860

6.  Local and Global Function Model of the Liver.

Authors:  Hesheng Wang; Mary Feng; Andrew Jackson; Randall K Ten Haken; Theodore S Lawrence; Yue Cao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-09       Impact factor: 7.038

7.  Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Krithika Suresh; Dawn Owen; Latifa Bazzi; William Jackson; Randall K Ten Haken; Kyle Cuneo; Mary Feng; Theodore S Lawrence; Matthew J Schipper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-09-22       Impact factor: 7.038

8.  Modeling of Normal Tissue Complications Using Imaging and Biomarkers After Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Issam El Naqa; Adam Johansson; Dawn Owen; Kyle Cuneo; Yue Cao; Martha Matuszak; Latifa Bazzi; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-01       Impact factor: 7.038

9.  Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.

Authors:  Mary Feng; Krithika Suresh; Matthew J Schipper; Latifa Bazzi; Edgar Ben-Josef; Martha M Matuszak; Neehar D Parikh; Theodore H Welling; Daniel Normolle; Randall K Ten Haken; Theodore S Lawrence
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

10.  Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma.

Authors:  Yaoru Huang; Shang-Wen Chen; Ching-Chao Fan; Lai-Lei Ting; Chia-Chun Kuo; Jeng-Fong Chiou
Journal:  Radiat Oncol       Date:  2016-07-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.